Aclaris Therapeutics (NASDAQ:ACRS) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a report published on Saturday morning.

A number of other research analysts also recently issued reports on the stock. HC Wainwright raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, December 23rd. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target on the stock in a report on Tuesday, November 19th. Leerink Partners upgraded Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Finally, Cantor Fitzgerald raised Aclaris Therapeutics to a “strong-buy” rating in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $11.00.

Aclaris Therapeutics Price Performance

ACRS opened at $2.39 on Friday. The firm has a market capitalization of $170.72 million, a PE ratio of -4.60 and a beta of 0.50. The business’s 50-day moving average is $2.82 and its two-hundred day moving average is $2.07. Aclaris Therapeutics has a 1 year low of $0.95 and a 1 year high of $5.17.

Insider Activity at Aclaris Therapeutics

In other Aclaris Therapeutics news, Director Anand Mehra purchased 666,666 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $2.25 per share, for a total transaction of $1,499,998.50. Following the acquisition, the director now owns 710,030 shares in the company, valued at $1,597,567.50. This represents a 1,537.37 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.40% of the stock is owned by insiders.

Institutional Trading of Aclaris Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC raised its holdings in shares of Aclaris Therapeutics by 1.9% during the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock worth $3,671,000 after purchasing an additional 63,358 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Aclaris Therapeutics during the 3rd quarter worth about $214,000. BML Capital Management LLC raised its stake in shares of Aclaris Therapeutics by 9.7% during the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock valued at $16,388,000 after buying an additional 1,261,866 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Aclaris Therapeutics by 187.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 216,826 shares during the period. Finally, Stonepine Capital Management LLC lifted its holdings in shares of Aclaris Therapeutics by 27.6% in the 3rd quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock valued at $2,828,000 after buying an additional 531,427 shares during the period. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.